Autor: "Reinisch, Walter" - OpacWWW

Skocz do pozycji: 1.

Tytuł:: Subcutaneous Infliximab Monotherapy Versus Combination Therapy with Immunosuppressants in Inflammatory Bowel Disease: A Post Hoc Analysis of a Randomised Clinical Trial.
Autorzy:: D'Haens, Geert
Reinisch, Walter
Schreiber, Stefan
Cummings, Fraser
Irving, Peter M.
Ye, Byong Duk
Kim, Dong-Hyeon
Yoon, SangWook
Ben-Horin, Shomron; Pokaż więcej
Temat:: INFLAMMATORY bowel diseases
CROHN'S disease
IMMUNOSUPPRESSIVE agents
INFLIXIMAB
ULCERATIVE colitis
Źródło:: Clinical Drug Investigation; Apr2023, Vol. 43 Issue 4, p277-288, 12p

Czasopismo naukowe

na półce

Szczegóły

Skocz do pozycji: 2.

Tytuł:: Categorising Endoscopic Severity of Crohn's Disease Using the Modified Multiplier SES-CD [MM-SES-CD].
Autorzy:: Narula N; Department of Medicine and Farncombe Family Digestive Health Research Institute; McMaster University, Hamilton, ON, Canada.
Pray C; Department of Medicine and Farncombe Family Digestive Health Research Institute; McMaster University, Hamilton, ON, Canada.
Wong ECL; Department of Medicine and Farncombe Family Digestive Health Research Institute; McMaster University, Hamilton, ON, Canada.
Colombel JF; Division of Gastroenterology; Icahn School of Medicine at Mount Sinai, New York, NY, USA.
Marshall JK; Department of Medicine and Farncombe Family Digestive Health Research Institute; McMaster University, Hamilton, ON, Canada.
Daperno M; Department of Internal Medicine, AO Ordine Mauriziano di Torino, Turin, Italy.
Reinisch W; Department of Internal Medicine III, Medical University of Vienna, Vienna, Austria.
Dulai PS; Division of Gastroenterology, Northwestern University, Chicago, IL,USA.; Pokaż więcej
Źródło:: Journal of Crohn's & colitis [J Crohns Colitis] 2022 Aug 04; Vol. 16 (7), pp. 1011-1019.
Typ publikacji:: Journal Article
MeSH Terms:: Crohn Disease*/diagnostic imaging
Crohn Disease*/drug therapy
Endoscopy, Gastrointestinal ; Humans ; Prognosis ; Severity of Illness Index

Czasopismo naukowe

na półce

Pełny tekst Pełny tekst Szczegóły

Skocz do pozycji: 3.

Tytuł:: Comparative efficacy and safety of infliximab and vedolizumab therapy in patients with inflammatory bowel disease: a systematic review and meta-analysis.
Autorzy:: Peyrin-Biroulet L; Centre Hospitalier Régional Universitaire de Nancy, Nancy, France.
Arkkila P; Department of Gastroenterology, Helsinki University and Helsinki University Hospital, Helsinki, Finland.
Armuzzi A; Humanitas Research Hospital, Milan, Rozzano, Italy.
Danese S; Gastroenterology and Endoscopy, University Vita-Salute San Raffaele, Milan, Italy.
Guardiola J; Digestive Diseases Department, Bellvitge University Hospital, Bellvitge Biomedical Research Institute-IDIBELL, University of Barcelona, L'Hospitalet de Llobregat, Barcelona, Spain.
Jahnsen J; Department of Gastroenterology, Institute of Clinical Medicine, Akershus University Hospital, University of Oslo, Oslo, Norway.
Lees C; Center of Genomics and Experimental Medicine, University of Edinburgh, Edinburgh, UK.
Louis E; Department of Gastroenterology, University Hospital CHU of Liège, Liège, Belgium.
Lukáš M; ISCARE Clinical Centre, Prague, Czech Republic.
Reinisch W; Medical University of Vienna, Vienna, Austria.
Roblin X; University Hospital of Saint-Etienne, Saint-Etienne, France.
Jang M; Celltrion Healthcare, Incheon, Republic of Korea.
Byun HG; Celltrion Healthcare, Incheon, Republic of Korea.
Kim DH; Celltrion Healthcare, Incheon, Republic of Korea.
Lee SJ; Celltrion Healthcare, Incheon, Republic of Korea.
Atreya R; Medical Department 1, University Hospital Erlangen, Friedrich-Alexander-University of Erlangen-Nürnberg, Ulmenweg 18, 91054, Erlangen, Germany. .; Pokaż więcej
Źródło:: BMC gastroenterology [BMC Gastroenterol] 2022 Jun 08; Vol. 22 (1), pp. 291. Date of Electronic Publication: 2022 Jun 08.
Typ publikacji:: Journal Article; Meta-Analysis; Systematic Review
MeSH Terms:: Colitis, Ulcerative*/chemically induced
Colitis, Ulcerative*/drug therapy
Crohn Disease*/chemically induced
Crohn Disease*/drug therapy
Inflammatory Bowel Diseases*/chemically induced
Inflammatory Bowel Diseases*/drug therapy
Adult ; Antibodies, Monoclonal, Humanized ; Gastrointestinal Agents/adverse effects ; Humans ; Infliximab/adverse effects

Czasopismo naukowe

na półce

Pełny tekst Pełny tekst Szczegóły

Skocz do pozycji: 4.

Tytuł:: Resolution of dominant patient-reported outcome at end of induction predicts clinical and endoscopic remission in Crohn's disease.
Autorzy:: Wong ECL; Department of Medicine, Division of Gastroenterology and Farncombe Family Digestive Health Research Institute, McMaster University, Hamilton, Ontario, Canada.
Dulai PS; Division of Gastroenterology, Northwestern University, Chicago, Illinois, USA.
Marshall JK; Department of Medicine, Division of Gastroenterology and Farncombe Family Digestive Health Research Institute, McMaster University, Hamilton, Ontario, Canada.
Jairath V; Department of Medicine, Division of Gastroenterology, Western University, London, Ontario, Canada.
Reinisch W; Department of Internal Medicine III, Division of Gastroenterology and Hepatology, Medical University of Vienna, Vienna, Austria.
Narula N; Department of Medicine, Division of Gastroenterology and Farncombe Family Digestive Health Research Institute, McMaster University, Hamilton, Ontario, Canada.; Pokaż więcej
Źródło:: Alimentary pharmacology & therapeutics [Aliment Pharmacol Ther] 2022 May; Vol. 55 (9), pp. 1151-1159. Date of Electronic Publication: 2022 Feb 15.
Typ publikacji:: Clinical Trial; Journal Article
MeSH Terms:: Biological Products*/therapeutic use
Crohn Disease*/diagnosis
Crohn Disease*/drug therapy
Endoscopy ; Humans ; Patient Reported Outcome Measures ; Remission Induction

Czasopismo naukowe

na półce

Pełny tekst Pełny tekst Szczegóły

Skocz do pozycji: 5.

Tytuł:: Editorial: is it not just PROs, but the most important individual PRO, that really matters in Crohn's disease? Authors' reply.
Autorzy:: Wong ECL; Department of Medicine (Division of Gastroenterology) and Farncombe Family Digestive Health Research Institute, McMaster University, Hamilton, Ontario, Canada.
Dulai PS; Division of Gastroenterology, Northwestern University, Chicago, Illinois, USA.
Marshall JK; Department of Medicine (Division of Gastroenterology) and Farncombe Family Digestive Health Research Institute, McMaster University, Hamilton, Ontario, Canada.
Jairath V; Department of Medicine, Division of Gastroenterology, Western University, London, Ontario, Canada.
Reinisch W; Department of Internal Medicine III, Division of Gastroenterology and Hepatology, Medical University of Vienna, Vienna, Austria.
Narula N; Department of Medicine (Division of Gastroenterology) and Farncombe Family Digestive Health Research Institute, McMaster University, Hamilton, Ontario, Canada.; Pokaż więcej
Źródło:: Alimentary pharmacology & therapeutics [Aliment Pharmacol Ther] 2022 Apr; Vol. 55 (8), pp. 1040-1041.
Typ publikacji:: Letter; Comment
MeSH Terms:: Crohn Disease*/diagnosis
Humans

Opinia redakcyjna

na półce

Pełny tekst Pełny tekst Szczegóły

Skocz do pozycji: 6.

Tytuł:: Outcomes of Passable and Non-passable Strictures in Clinical Trials of Crohn's Disease: A Post-hoc Analysis.
Autorzy:: Narula N; Department of Medicine [Division of Gastroenterology] and Farncombe Family Digestive Health Research Institute, M cmaster University, Hamilton, ON, Canada.
Wong ECL; Department of Medicine [Division of Gastroenterology] and Farncombe Family Digestive Health Research Institute, M cmaster University, Hamilton, ON, Canada.
Dulai PS; Division of Gastroenterology, University of California San Diego, La Jolla, CA, USA.
Marshall JK; Department of Medicine [Division of Gastroenterology] and Farncombe Family Digestive Health Research Institute, M cmaster University, Hamilton, ON, Canada.
Colombel JF; Division of Gastroenterology; Icahn School of Medicine at Mount Sinai, New York, NY, USA.
Reinisch W; Department of Internal Medicine III, Division of Gastroenterology and Hepatology, Medical University of Vienna, Vienna, Austria.; Pokaż więcej
Źródło:: Journal of Crohn's & colitis [J Crohns Colitis] 2021 Oct 07; Vol. 15 (10), pp. 1649-1657.
Typ publikacji:: Journal Article
MeSH Terms:: Remission Induction*
Constriction, Pathologic/*drug therapy
Crohn Disease/*drug therapy
Adult ; Azathioprine/therapeutic use ; Clinical Trials as Topic ; Endoscopy, Gastrointestinal ; Female ; Gastrointestinal Agents/therapeutic use ; Humans ; Immunosuppressive Agents/therapeutic use ; Infliximab/therapeutic use ; Male ; Ustekinumab/therapeutic use

Czasopismo naukowe

na półce

Pełny tekst Pełny tekst Szczegóły

Skocz do pozycji: 7.

Tytuł:: End of Induction Patient-reported Outcomes Predict Clinical Remission but Not Endoscopic Remission in Crohn's Disease.
Autorzy:: Wong ECL; Department of Medicine [Division of Gastroenterology] and Farncombe Family Digestive Health Research Institute, McMaster University, Hamilton ON, Canada.
Buffone E; Department of Medicine, McGill University, Montreal, QC, Canada.
Lee SJ; Department of Medicine [Division of Gastroenterology] and Farncombe Family Digestive Health Research Institute, McMaster University, Hamilton ON, Canada.
Dulai PS; Division of Gastroenterology, University of California San Diego, La Jolla, CA, USA.
Marshall JK; Department of Medicine [Division of Gastroenterology] and Farncombe Family Digestive Health Research Institute, McMaster University, Hamilton ON, Canada.
Reinisch W; Department of Internal Medicine III, Division of Gastroenterology and Hepatology, Medical University of Vienna, Vienna, Austria.
Narula N; Department of Medicine [Division of Gastroenterology] and Farncombe Family Digestive Health Research Institute, McMaster University, Hamilton ON, Canada.; Pokaż więcej
Źródło:: Journal of Crohn's & colitis [J Crohns Colitis] 2021 Jul 05; Vol. 15 (7), pp. 1114-1119.
Typ publikacji:: Journal Article
MeSH Terms:: Patient Reported Outcome Measures*
Crohn Disease/*drug therapy
Gastrointestinal Agents/*therapeutic use
Infliximab/*therapeutic use
Adult ; Colonoscopy ; Female ; Humans ; Male ; Prognosis ; Remission Induction

Czasopismo naukowe

na półce

Pełny tekst Szczegóły

Skocz do pozycji: 8.

Tytuł:: Week 6 Calprotectin Best Predicts Likelihood of Long-term Endoscopic Healing in Crohn's Disease: A Post-hoc Analysis of the UNITI/IM-UNITI Trials.
Autorzy:: Narula N; Department of Medicine [Division of Gastroenterology] and Farncombe Family Digestive Health Research Institute, McMaster University, Hamilton, ON, Canada.
Wong ECL; Department of Medicine [Division of Gastroenterology] and Farncombe Family Digestive Health Research Institute, McMaster University, Hamilton, ON, Canada.
Dulai PS; Division of Gastroenterology, University of California San Diego, La Jolla, CA, USA.
Marshall JK; Department of Medicine [Division of Gastroenterology] and Farncombe Family Digestive Health Research Institute, McMaster University, Hamilton, ON, Canada.
Colombel JF; Division of Gastroenterology; Icahn School of Medicine at Mount Sinai, New York, NY, USA.
Reinisch W; Department of Internal Medicine III, Division of Gastroenterology and Hepatology, Medical University of Vienna, Vienna, Austria.; Pokaż więcej
Źródło:: Journal of Crohn's & colitis [J Crohns Colitis] 2021 Mar 05; Vol. 15 (3), pp. 462-470.
Typ publikacji:: Journal Article
MeSH Terms:: Remission Induction*
Crohn Disease/*drug therapy
Feces/*chemistry
Leukocyte L1 Antigen Complex/*analysis
Adult ; Biomarkers/analysis ; Endoscopy, Gastrointestinal ; Female ; Gastrointestinal Agents/therapeutic use ; Humans ; Male ; Randomized Controlled Trials as Topic ; Ustekinumab/therapeutic use

Czasopismo naukowe

na półce

Pełny tekst Pełny tekst Szczegóły

Skocz do pozycji: 9.

Tytuł:: A Randomized Controlled Trial of the Efficacy and Safety of CCX282-B, an Orally-Administered Blocker of Chemokine Receptor CCR9, for Patients with Crohn’s Disease.
Autorzy:: Keshav, Satish
Vaňásek, Tomáš
Niv, Yaron
Petryka, Robert
Howaldt, Stephanie
Bafutto, Mauro
Rácz, István
Hetzel, David
Nielsen, Ole Haagen
Vermeire, Séverine
Reinisch, Walter
Karlén, Per
Schreiber, Stefan
Schall, Thomas J.
Bekker, Pirow; Pokaż więcej
Temat:: INFLAMMATORY bowel disease treatment
RANDOMIZED controlled trials
CHEMOKINE receptors
ORAL drug administration
INFLAMMATION
MEDICAL statistics
CLINICAL trials
IMMUNOLOGY
Źródło:: PLoS ONE; Mar2013, Vol. 8 Issue 3, p1-12, 12p

Czasopismo naukowe

na półce

Pełny tekst Szczegóły

Skocz do pozycji: 10.

Tytuł:: Extracorporeal photopheresis: Past, present, and future.
Autorzy:: Knobler, Robert
Barr, Mark L.
Couriel, Daniel R.
Ferrara, James L.M.
French, Lars E.
Jaksch, Peter
Reinisch, Walter
Rook, Alain H.
Schwarz, Thomas
Greinix, Hildegard; Pokaż więcej
Źródło:: Journal of the American Academy of Dermatology; Oct2009, Vol. 61 Issue 4, p652-665, 14p

Czasopismo naukowe

na półce

Szczegóły

Skocz do pozycji: 11.

Tytuł:: Effect of PF-00547659 on Central Nervous System Immune Surveillance and Circulating β7+ T Cells in Crohn's Disease: Report of the TOSCA Study.
Autorzy:: D'Haens G; Academic Medical Center, Amsterdam, The Netherlands.
Vermeire S; Leuven University Hospital, Leuven, Belgium.
Vogelsang H; Medical University of Vienna, Vienna, Austria.
Allez M; Hôpital Saint-Louis, Université Paris Diderot, Paris, France.
Desreumaux P; University of Lille, Lille, France.
Van Gossum A; Erasme Hospital, Free University of Brussels, Brussels, Belgium.
Sandborn WJ; University of California San Diego, La Jolla, CA, USA.
Baumgart DC; Charité Medical School, Humboldt-University of Berlin, Berlin, Germany.
Ransohoff RM; Mellen Center for MS Treatment and Research, Cleveland Clinic, Cleveland, OH, USA.
Comer GM; Kimberton Drug Development Consulting, Phoenixville, PA, USA.
Ahmad A; Pfizer, Cambridge, MA, USA.
Cataldi F; Pfizer, Cambridge, MA, USA.
Cheng J; Pfizer, Cambridge, MA, USA.
Clare R; Pfizer, Cambridge, MA, USA.
Gorelick KJ; Pfizer, Cambridge, MA, USA.
Kaminski A; Pfizer, Cambridge, MA, USA.
Pradhan V; Pfizer, Cambridge, MA, USA.
Rivers S; Pfizer, Cambridge, MA, USA.
Sikpi MO; Pfizer, Cambridge, MA, USA.
Zhang Y; Pfizer, Cambridge, MA, USA.
Hassan-Zahraee M; Pfizer, Cambridge, MA, USA.
Reinisch W; Medical University of Vienna, Vienna, Austria.; McMaster University, Hamilton, ON, Canada.
Stuve O; Neurology Section, VA North Texas Health Care System, Dallas, TX, USA.; Southwestern Medical Center, University of Texas, Dallas, TX, USA.; Department of Neurology, Klinikum rechts der Isar, Technische Universität München, Germany.; Pokaż więcej
Źródło:: Journal of Crohn's & colitis [J Crohns Colitis] 2018 Jan 24; Vol. 12 (2), pp. 188-196.
Typ publikacji:: Journal Article
MeSH Terms:: Antibodies, Monoclonal, Humanized/*therapeutic use
Central Nervous System/*immunology
Crohn Disease/*immunology
Integrin beta Chains/*metabolism
T-Lymphocytes/*metabolism
Adolescent ; Adult ; Antibodies, Monoclonal, Humanized/pharmacology ; Crohn Disease/blood ; Crohn Disease/cerebrospinal fluid ; Female ; Humans ; Immunologic Surveillance/drug effects ; Immunosuppressive Agents/therapeutic use ; Leukoencephalopathy, Progressive Multifocal/chemically induced ; Lymphocyte Count ; Male ; Middle Aged ; T-Lymphocyte Subsets ; Young Adult

Czasopismo naukowe

na półce

Pełny tekst Pełny tekst Szczegóły

Skocz do pozycji: 12.

Tytuł:: Exposure-efficacy Relationships for Vedolizumab Induction Therapy in Patients with Ulcerative Colitis or Crohn's Disease.
Autorzy:: Rosario M; Clinical Pharmacology Department, Millennium Pharmaceuticals Inc., a wholly owned subsidiary of Takeda Pharmaceutical Company Ltd, Cambridge, MA, USA.
French JL; Metrum Research Group LLC, Tariffville, CT, USA.
Dirks NL; Metrum Research Group LLC, Tariffville, CT, USA.
Sankoh S; Clinical Pharmacology Department, Millennium Pharmaceuticals Inc., a wholly owned subsidiary of Takeda Pharmaceutical Company Ltd, Cambridge, MA, USA.
Parikh A; Clinical Pharmacology Department, Millennium Pharmaceuticals Inc., a wholly owned subsidiary of Takeda Pharmaceutical Company Ltd, Cambridge, MA, USA.
Yang H; Clinical Pharmacology Department, Millennium Pharmaceuticals Inc., a wholly owned subsidiary of Takeda Pharmaceutical Company Ltd, Cambridge, MA, USA.
Danese S; Inflammatory Bowel Disease Clinical and Research Unit, Istituto Clinico Humanitas, Milan, Italy.
Colombel JF; Icahn School of Medicine at Mount Sinai Hospital, New York, NY, USA.
Smyth M; Takeda Development Centre Europe Ltd, London, UK.
Sandborn WJ; Division of Gastroenterology, University of California San Diego, La Jolla, CA, USA.
Feagan BG; Robarts Research Institute, University of Western Ontario, London, ON, Canada.
Reinisch W; Department of Internal Medicine III, Medical University of Vienna, Vienna, Austria, and Department of Internal Medicine, McMaster University, Hamilton, ON, Canada.
Sands BE; Icahn School of Medicine at Mount Sinai Hospital, New York, NY, USA.
Sans M; Digestive Diseases Service, Centro Médico Teknon, Barcelona, Spain.
Fox I; Clinical Pharmacology Department, Millennium Pharmaceuticals Inc., a wholly owned subsidiary of Takeda Pharmaceutical Company Ltd, Cambridge, MA, USA.; Pokaż więcej
Źródło:: Journal of Crohn's & colitis [J Crohns Colitis] 2017 Aug 01; Vol. 11 (8), pp. 921-929.
Typ publikacji:: Journal Article; Randomized Controlled Trial
MeSH Terms:: Antibodies, Monoclonal, Humanized/*therapeutic use
Colitis, Ulcerative/*drug therapy
Crohn Disease/*drug therapy
Gastrointestinal Agents/*therapeutic use
Adolescent ; Adult ; Aged ; Aged, 80 and over ; Antibodies, Monoclonal, Humanized/administration & dosage ; Antibodies, Monoclonal, Humanized/blood ; Dose-Response Relationship, Drug ; Double-Blind Method ; Feces/chemistry ; Female ; Gastrointestinal Agents/administration & dosage ; Humans ; Leukocyte L1 Antigen Complex/analysis ; Male ; Middle Aged ; Remission Induction/methods ; Serum Albumin/analysis ; Treatment Outcome ; Young Adult

Czasopismo naukowe

na półce

Pełny tekst Szczegóły

Skocz do pozycji: 13.

Tytuł:: Five-year Safety Data From ENCORE, a European Observational Safety Registry for Adults With Crohn's Disease Treated With Infliximab [Remicade®] or Conventional Therapy.
Autorzy:: D'Haens G; Department of Gastroenterology, Academic MedicalCenter, Amsterdam, The Netherlands.
Reinisch W; Klinische Abt. Gastroenterologie & Hepatologie, Medical University, Vienna, Austria and McMaster University, Hamilton, ON, Canada.
Colombel JF; Division of Gastroenterology, Icahn School of Medicine at Mount Sinai, New York, NY, USA.
Panes J; Department of Gastroenterology, Hospital Clinic de Barcelona, IDIBAPS, CIBERehd, Barcelona, Spain.
Ghosh S; Department of Gastroenterology, University of Calgary, Calgary, AB, Canada.
Prantera C; Department of Gastroenterology, A.O. San Camillo Forlanini, Rome, Italy.
Lindgren S; Department of Gastroenterology, Lund University, University Hospital Skane, Malmö, Sweden.
Hommes DW; Centre for Inflammatory Bowel Diseases, Univerisity of California Los Angeles, Los Angeles, CA, USA.
Huang Z; Centre for Biostatistics, Merck Inc., Kenilworth, NJ, USA.
Boice J; Centre for Biostatistics, Merck Inc., Kenilworth, NJ, USA.
Huyck S; Centre for Biostatistics, Merck Inc., Kenilworth, NJ, USA.
Cornillie F; Global Medical Affairs, MSD International GmbH, Lucerne, Switzerland.; Pokaż więcej
Corporate Authors:: ENCORE investigators
Źródło:: Journal of Crohn's & colitis [J Crohns Colitis] 2017 Jun 01; Vol. 11 (6), pp. 680-689.
Typ publikacji:: Journal Article; Observational Study
MeSH Terms:: Crohn Disease/*drug therapy
Gastrointestinal Agents/*adverse effects
Hematologic Diseases/*chemically induced
Infections/*chemically induced
Infliximab/*adverse effects
Adolescent ; Adult ; Aged ; Aged, 80 and over ; Anti-Bacterial Agents/adverse effects ; Anti-Inflammatory Agents/adverse effects ; Azathioprine/adverse effects ; Demyelinating Diseases/chemically induced ; Drug Substitution ; Drug Therapy, Combination/adverse effects ; Female ; Humans ; Immunosuppressive Agents/adverse effects ; Infusions, Intravenous/adverse effects ; Lymphoproliferative Disorders/chemically induced ; Male ; Mercaptopurine/adverse effects ; Mesalamine/adverse effects ; Methotrexate/adverse effects ; Middle Aged ; Mortality ; Narcotics/adverse effects ; Prednisone/adverse effects ; Prospective Studies ; Registries ; Risk Factors ; Sulfasalazine/adverse effects ; Time Factors ; Young Adult

Czasopismo naukowe

na półce

Pełny tekst Szczegóły

Skocz do pozycji: 14.

Tytuł:: Characterisation of Mucosal Healing with Adalimumab Treatment in Patients with Moderately to Severely Active Crohn's Disease: Results from the EXTEND Trial.
Autorzy:: Reinisch W; Division of Gastroenterology, Department of Medicine, McMaster University, Hamilton, ON, Canada; and Department of Internal Medicine III, Division of Gastroenterology & Hepatology, Medical University of Vienna, Vienna, Austria.
Colombel JF; Dr. Henry D. Janowitz Division of Gastroenterology, Icahn School of Medicine at Mount Sinai, New York, NY, USA.
D'Haens G; Department of Gastroenterology, Academic Medical Center, Amsterdam, The Netherlands; and Imelda GI Clinical Research Center, Bonheiden, Belgium.
Sandborn WJ; Division of Gastroenterology, University of California San Diego, La Jolla, CA, USA.
Rutgeerts P; Division of Gastroenterology, Department of Internal Medicine, University of Leuven, Leuven, Belgium.
Geboes K; Department of Pathology, University of Leuven, Leuven, Belgium.
Petersson J; Global Medical Affairs Gastroenterology, AbbVie Inc., North Chicago, IL, USA.
Eichner S; Global Medical Affairs Gastroenterology, AbbVie Inc., North Chicago, IL, USA.
Zhou Q; Data and Statistical Sciences, AbbVie Inc., North Chicago, IL, USA.
Robinson AM; Global Medical Affairs Gastroenterology, AbbVie Inc., North Chicago, IL, USA.
Read HA; Global Medical Affairs Gastroenterology, AbbVie Inc., North Chicago, IL, USA.
Thakkar R; Global Medical Affairs Gastroenterology, AbbVie Inc., North Chicago, IL, USA.; Pokaż więcej
Źródło:: Journal of Crohn's & colitis [J Crohns Colitis] 2017 Apr 01; Vol. 11 (4), pp. 425-434.
Typ publikacji:: Journal Article; Randomized Controlled Trial
MeSH Terms:: Adalimumab/*therapeutic use
Crohn Disease/*drug therapy
Adult ; Colonoscopy ; Crohn Disease/pathology ; Double-Blind Method ; Female ; Humans ; Intestinal Mucosa/pathology ; Male ; Treatment Outcome

Czasopismo naukowe

na półce

Pełny tekst Szczegóły

Skocz do pozycji: 15.

Tytuł:: Results of the Fifth Scientific Workshop of the ECCO [II]: Clinical Aspects of Perianal Fistulising Crohn's Disease-the Unmet Needs.
Autorzy:: Gecse KB; First Department of Medicine, Semmelweis University, Budapest, Hungary .
Sebastian S; Inflammatory Bowel Disease Unit, Hull & East Yorkshire NHS Trust, Hull, UK.
Hertogh Gd; Department of Pathology, University of Leuven, Leuven, Belgium.
Yassin NA; Department of Colorectal Surgery, St Mark's Hospital and Academic Institute, London, UK.
Kotze PG; Colorectal Surgery Unit, Catholic University of Paraná, Curitiba, PR, Brazil.
Reinisch W; Division of Gastroenterology, Department of Medicine, McMaster University, Hamilton, ON, Canada.
Spinelli A; Colorectal Surgery Unit, Humanitas Research Hospital, Humanitas University, Milan, Italy.
Koutroubakis IE; Department of Gastroenterology, University Hospital Heraklion, Iraklio, Greece.
Katsanos KH; Division of Gastroenterology, Department of Medicine, School of Health Sciences, Ioannina, Greece.
Hart A; Inflammatory Bowel Disease Unit, St Mark's Hospital, London, UK.
van den Brink GR; Department of Gastroenterology, Academic Medical Centre, University of Amsterdam, Amsterdam, The Netherlands.
Rogler G; Division of Gastroenterology and Hepatology, University Hospital Zürich, Zürich, Switzerland.
Bemelman WA; Department of Surgery, Academic Medical Center, University of Amsterdam, Amsterdam, The Netherlands.; Pokaż więcej
Źródło:: Journal of Crohn's & colitis [J Crohns Colitis] 2016 Jul; Vol. 10 (7), pp. 758-65. Date of Electronic Publication: 2016 Jan 28.
Typ publikacji:: Consensus Development Conference; Journal Article; Systematic Review
MeSH Terms:: Crohn Disease/*physiopathology
Rectal Fistula/*etiology
Crohn Disease/therapy ; Humans ; Magnetic Resonance Imaging ; Outcome Assessment, Health Care/methods ; Rectal Fistula/diagnosis ; Rectal Fistula/pathology ; Rectal Fistula/therapy ; Severity of Illness Index

Czasopismo naukowe

na półce

Pełny tekst Szczegóły

Skocz do pozycji: 16.

Tytuł:: Development of Red Flags Index for Early Referral of Adults with Symptoms and Signs Suggestive of Crohn's Disease: An IOIBD Initiative.
Autorzy:: Danese S; IBD Center, Humanitas Research Hospital, Rozzano, Milan, Italy .
Fiorino G; IBD Center, Humanitas Research Hospital, Rozzano, Milan, Italy.
Mary JY; Inserm U1153 - SBIM Hôpital Saint-Louis, Paris, France.
Lakatos PL; 1st Department of Medicine, Semmelweis University, Budapest, Hungary.
D'Haens G; IBD Unit, Gastroenterology, Amsterdam Medical Center, Amsterdam, The Netherlands.
Moja L; Department of Biomedical Sciences for Health, University of Milan, Milan, Italy Unit of Clinical Epidemiology, IRCCS Galeazzi Orthopedic Institute, Milan, Italy.
D'Hoore A; Abdominal Surgery, UZ Leuven, Leuven, Belgium.
Panes J; Gastroenterology Department, Hospital Clinic of Barcelona, IDIPABS, CIBERehd, Barcelona, Spain.
Reinisch W; Medizinische Universität Wien, Klinische Abt. Gastroenterologie & Hepatologie, AKH Wien, Austria.
Sandborn WJ; Division of Gastroenterology, UC San Diego Health System, La Jolla, CA, USA.
Travis SP; Translational Gastroenterology Unit, John Radcliffe Hospital, Oxford, UK.
Vermeire S; Department of Gastroenterology, University Hospitals Leuven, Leuven, Belgium.
Peyrin-Biroulet L; Department of Hepato-Gastroenterology and Inserm U954, Nancy University Hospital, Lorraine University, Vandoeuvre-lès-Nancy, France.
Colombel JF; Department of Gastroenterology, Icahn Medical School at Mount Sinai, New York, NY, USA.; Pokaż więcej
Źródło:: Journal of Crohn's & colitis [J Crohns Colitis] 2015 Aug; Vol. 9 (8), pp. 601-6. Date of Electronic Publication: 2015 Apr 23.
Typ publikacji:: Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't
MeSH Terms:: Decision Support Techniques*
Health Status Indicators*
Referral and Consultation*
Crohn Disease/*diagnosis
Adult ; Cross-Sectional Studies ; Delayed Diagnosis/prevention & control ; Early Diagnosis ; Humans ; Risk Assessment ; Sensitivity and Specificity ; Surveys and Questionnaires